Regeneron (REGN) Q3 Earnings Beat, REGEN-COV Boosts Growth Posted byZacks Equity Research November 4, 2021 Leave a comment on Regeneron (REGN) Q3 Earnings Beat, REGEN-COV Boosts Growth Regeneron (REGN) beats on Q3 earnings while sales record strong year-over-year growth on the solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.